IDEXX Laboratories (NASDAQ:IDXX) had its price target hoisted by Credit Suisse Group from $415.00 to $422.00 in a research report report published on Monday, The Fly reports. Credit Suisse Group currently has an outperform rating on the stock.
A number of other equities research analysts also recently commented on IDXX. BidaskClub downgraded IDEXX Laboratories from a strong-buy rating to a buy rating in a report on Friday, August 14th. Bank of America increased their price objective on shares of IDEXX Laboratories from $300.00 to $390.00 and gave the company a buy rating in a research note on Monday, July 20th. Stifel Nicolaus lifted their target price on shares of IDEXX Laboratories from $280.00 to $375.00 and gave the stock a buy rating in a research report on Thursday, July 30th. Finally, TheStreet raised shares of IDEXX Laboratories from a c+ rating to a b- rating in a report on Thursday, April 30th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. IDEXX Laboratories currently has a consensus rating of Buy and a consensus price target of $344.00.
IDEXX Laboratories stock opened at $383.33 on Monday. IDEXX Laboratories has a one year low of $168.65 and a one year high of $407.86. The company has a debt-to-equity ratio of 3.54, a quick ratio of 1.02 and a current ratio of 1.44. The business has a fifty day moving average of $362.94 and a two-hundred day moving average of $296.80. The company has a market cap of $32.45 billion, a P/E ratio of 72.46, a price-to-earnings-growth ratio of 4.40 and a beta of 0.85.
IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Friday, July 31st. The company reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.17 by $0.55. IDEXX Laboratories had a return on equity of 241.52% and a net margin of 18.59%. The company had revenue of $637.20 million during the quarter, compared to the consensus estimate of $589.98 million. During the same quarter last year, the company earned $1.43 earnings per share. IDEXX Laboratories’s quarterly revenue was up 2.8% compared to the same quarter last year. Sell-side analysts predict that IDEXX Laboratories will post 5.66 EPS for the current year.
In related news, Director M Anne Szostak sold 7,722 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $306.91, for a total transaction of $2,369,959.02. Following the sale, the director now owns 7,722 shares in the company, valued at $2,369,959.02. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brian P. Mckeon sold 83,724 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $378.97, for a total transaction of $31,728,884.28. Following the sale, the chief financial officer now owns 58,386 shares in the company, valued at approximately $22,126,542.42. The disclosure for this sale can be found here. Insiders sold a total of 115,032 shares of company stock valued at $42,064,375 in the last three months. 2.53% of the stock is currently owned by corporate insiders.
Several large investors have recently made changes to their positions in IDXX. Steward Partners Investment Advisory LLC lifted its position in IDEXX Laboratories by 155.0% during the second quarter. Steward Partners Investment Advisory LLC now owns 102 shares of the company’s stock worth $34,000 after buying an additional 62 shares during the period. Key Financial Inc acquired a new position in shares of IDEXX Laboratories during the 1st quarter valued at about $36,000. Anderson Fisher LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $36,000. Cullen Frost Bankers Inc. purchased a new position in shares of IDEXX Laboratories during the 2nd quarter worth about $36,000. Finally, Tompkins Financial Corp acquired a new stake in shares of IDEXX Laboratories in the first quarter worth approximately $38,000. 88.58% of the stock is owned by institutional investors and hedge funds.
About IDEXX Laboratories
IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.
See Also: Net Income
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.